Content Conference Coverage Conferences AASLD 2013
AASLD Liver Meeting Starts this Weekend in Washington, DC
- Details
- Category: Hepatitis B
- Created on Wednesday, 30 October 2013 00:00
The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.
AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
- Details
- Category: HBV Treatment
- Created on Wednesday, 04 December 2013 00:00
Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.
AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk
- Details
- Category: HBV Treatment
- Created on Wednesday, 06 November 2013 00:00
Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B virus (HBV) infection will develop hepatocellular carcinoma, according to findings presented this week at the 64thAASLD Liver Meeting in Washington, DC. Another study, however, found that while entecavir or tenofovir can reduce the risk, people with hepatitis B should continue to undergo regular monitoring for liver cancer, and better predictive models may be needed for Caucasian patients.
AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Created on Tuesday, 12 November 2013 00:00
A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.
Coverage of the 2013 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Created on Wednesday, 30 October 2013 00:00
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
10/30/13
More Articles...
- AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
- AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years
- AASLD 2013: Viral Hepatitis Epidemics in the U.S. and California
- AASLD 2013: Liver Meeting Ends with Hepatitis C Debrief and the Future of Treatment
- AASLD 2013: Liver Meeting Opens with a Focus on Hepatitis C
- AASLD 2013: MK-5172 + Ribavirin Works Well for People with Hepatitis C Genotype 1b
- AASLD 2013: Sofosbuvir + Ribavirin Effective Against Hepatitis C Genotype 4
- AASLD 2013: Faldaprevir Triple Therapy Effective Across Patient Subgroups
- AASLD 2013: Faldaprevir All-oral Regimen Shows 100% Early Sustained Response for HCV 1a
- AbbVie All-Oral Regimen Produces 96% Cure Rate, Effective Against Both HCV 1a and 1b
- AASLD 2013: Black Hepatitis C Patients Do Well on Sofosbuvir Oral Regimens
- AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C
- AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients
- AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study
- AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%
- AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence
- AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study
- AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
- AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
- AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
- AASLD 2013: Simeprevir + Sofosbuvir Produces High Sustained Response Rates for Hard-to-treat Patients
- AASLD 2013: HCV Levels in Semen May Correspond to Blood Viral Load
- AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women
- AASLD 2013: Veterans Study Supports CDC Recommendation to Screen Baby Boomers for Hep C
- AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated
- AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis
- AASLD 2013: Viral Hepatitis Is a Leading Cause of Death Worldwide
- AASLD 2013: Faldaprevir + Interferon/Ribavirin Leads to Early Sustained Response for HIV/HCV Coinfected
- AASLD 2013: Sofosbuvir + Ribavirin Produces Sustained Response in 76% of GT 1 HIV/HCV Coinfected Patients
- AASLD 2013: High Response Rates with Telaprevir Triple Therapy for HIV+ Men with Acute Hepatitis C
- AASLD 2013: Label Warnings, Counseling Do Not Eliminate Risk of Acetaminophen Toxicity
Web Design and Development by